Cost benefit analysis of intralesional injections in keloids using Luer lock and non-locking syringes
DOI:
https://doi.org/10.18203/issn.2455-4510.IntJResOrthop20240417Keywords:
Leur lock syringes, Keloid injection, Cost benefit analysis, SteroidAbstract
Background: For keloid scarring, intralesional corticosteroid injections continue to be the most often utilised first therapeutic option. This is a common procedure done on an outpatient basis by surgeons and orthopaedists. Luer lock syringes which lock the needle with syringe prevent any leakage or spillage of drug while pushing it near the keloid compared to normal syringes.
Methods: We intend to do a cost benefit analysis based on the retrospective data of intralesional steroid injections done by the authors (AP and SK) in their private practice.
Results: The time between 2021 to 2022, 200 injection data was retrieved, 100 each using non locking syringes and Luer lock syringes. The spillage rate with non-Luer lock syringes was 14%.
Conclusions: We found that luer lock syringes prove to be cost effective after giving more than 200 injections in keloids than non-locking syringes.
References
Trace AP, Enos CW, Mantel A, Harvey VM. Keloids and Hypertrophic Scars: A Spectrum of Clinical Challenges. Am J Clin Dermatol. 2016;17(3):201-23.
Insalaco L, Saxon S, Spiegel JH. What is the role of intralesional corticosteroid injections for keloids before considering surgery? Laryngoscope. 2016;126(3):549-50.
Ghazawi FM, Zargham R, Gilardino MS, Sasseville D, Jafarian F. Insights into the Pathophysiology of Hypertrophic Scars and Keloids: How Do They Differ? Adv Skin Wound Care. 2018;31(1):582-95.
Ogawa R. Keloid and Hypertrophic Scars Are the Result of Chronic Inflammation in the Reticular Dermis. Int J Mol Sci. 2017;18(3).
Andrews JP, Marttala J, Macarak E, Rosenbloom J, Uitto J. Keloids: The paradigm of skin fibrosis - Pathomechanisms and treatment. Matrix Biol. 2016;51:37-46.
Morelli Coppola M, Salzillo R, Segreto F, Persichetti P. Triamcinolone acetonide intralesional injection for the treatment of keloid scars: patient selection and perspectives. Clin Cosmet Investig Dermatol. 2018;11:387-96.
Wiepking F, Van Zundert A, Martin JP, Cazalaà JB, Buttner R. The all-glass Lüer syringe: Historical facts around concepts, introduction and patents. Anaesth Crit Care Pain Med. 2021;40(4):100921.
Boyer AL, Wang CC, Gitterman M. A Luer lock after loading device for iridium-192 brachytherapy. Int J Radiat Oncol Biol Phys. 1980;6(4):511-2.
Kuroiwa C, Suzuki A, Yamaji Y, Miyoshi M. Hidden reality on the introduction of auto-disable syringes in developing countries. Southeast Asian J Trop Med Public Health. 2004;35(4):1019-23.
Fletcher SJ. Failure of a Luer lock. Anaesthesia. 2005;60(2):206.
Yusop N, Williams GJ, Cooper C, Burton R, Samuel L, Maillard JY. Low-level microbial contamination of liquid in syringe hubs leads to an unacceptable risk to the end product. J Pharm Pharmacol. 2011;63(2):164-8.
